Nyxoah Seeks US Capital with Underwritten Offering and 15% Option to Fund Genio Commercialization
NYXH•Nyxoah launched an underwritten US public offering of ordinary shares with a 30-day option for 15% additional shares to fund Genio system US commercialization, R&D upgrades, cost reduction initiatives, clinical research and other corporate purposes. The company also began a search for a US-based CEO to accelerate its US growth.
1. Proposed Underwritten Offering
Nyxoah announced an underwritten public offering in the United States of ordinary shares, with all shares sold by the company and a 30-day option for underwriters to purchase up to 15% additional shares. The offering may include private placements to qualified investors outside the US, including within the European Union, and is subject to market conditions.
2. Use of Proceeds
Net proceeds will support expansion of Genio system commercialization in the US, finance R&D upgrades and cost reduction initiatives, build a pipeline of new technologies and explore collaborations in OSA monitoring and diagnostics. Remaining funds will advance international launches, clinical research projects, debt repayment, capital expenditures, potential acquisitions and general corporate purposes.
3. Leadership Transition Process
Nyxoah has commenced a search for a US-based Chief Executive Officer to lead its next phase of growth from within its largest target market. Founder Olivier Taelman will remain fully engaged during the transition to ensure operational continuity and support the incoming CEO’s successful onboarding.
